Titre : | Persistence of antidepressant treatment effects in a pharmacotherapy plus psychotherapy trial for active injection drug users |
Titre traduit : | (Persistance des effets antidépresseurs du traitement chez des usagers de drogues par injection suivant à la fois une pharmacothérapie et une psychothérapie.) |
Auteurs : | M. D. STEIN ; SOLOMON D. A. ; B. J. ANDERSON ; B. H. HERMAN ; J. L. ANTHONY ; R. A. BROWN ; S. E. RAMSEY ; I. W. MILLER |
Type de document : | Périodique |
Année de publication : | 2005 |
Format : | 346-357 / tabl. |
Note générale : |
American Journal on Addictions, 2005, 14, (4), 346-357 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés DEPRESSION ; PHARMACOTHERAPIE ; THERAPIE COMPORTEMENTALE ; PRISE EN CHARGE ; SUIVI DU PATIENT ; EFFICACITE |
Résumé : |
ENGLISH : The objective of this study was to determine if combined psychotherapy and pharmacotherapy reduces reported depressive symptoms compared to an assessment only condition for active drug injectors over nine months. Using a randomized controlled trial at an outpatient academic research office, the researchers applied psychotherapy (eight sessions of cognitive behavioral therapy) plus pharmacotherapy (citalopram) to active injection drug users with a DSM-IV diagnosis of major depression, dysthymia, substance-induced mood disorder with symptoms persisting for at least three months, or major depression plus dysthymia, and a Modified Hamilton Rating Scale for Depression (MHRSD) score greater than 13. The MHRSD scale scores were then assessed at the completion of three, six, and nine months. Participants (n = 109) were 64% male and 82% Caucasian, with a mean baseline MHRSD score of 20.7. Depression subtypes included major depression only (63%), substance-induced depression (17%), and double-depression (17%). Study retention at nine months was 89%. At the completion of three months of acute treatment, 26% of combined treatment patients (n = 53), compared to 12% of control patients (n = 56), were in remission (p = .047). At both six and nine months, the between-group differences in remission rates and mean MHRSD scores were insignificant, although the overall mean MHRSD score decreased from baseline (p |
Note de contenu : | tabl. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 36 |
Affiliation : |
Division of General Internal Medicine, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903. E-mail: msteinlifestan.org Etats-Unis. United States. |
Numéro Toxibase : | 208500 |
Centre Emetteur : | 02 Coordonnateur |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil